Literature DB >> 17942316

Clinicopathological investigation of pulmonary pleomorphic carcinoma.

Satoshi Yamamoto1, Daisuke Hamatake, Takao Ueno, Takao Higuchi, Masahumi Hiratsuka, Takeshi Shiraishi, Akinori Iwasaki, Takayuki Shirakusa.   

Abstract

BACKGROUND: Pleomorphic carcinoma is an uncommon malignant tumor of the lung. As there are few large-scale studies of patients with pleomorphic carcinoma, the clinical characteristics and behavior of the disease have been unclear until now. In this study, we investigated the clinicopathological findings and prognosis of 21 patients with pleomorphic carcinoma. PATIENTS AND METHODS: We identified 930 cases of pulmonary carcinoma in which the patient underwent a lung resection in our institute between January 1999 and June 2007. Of those patients, 21 (2.6%) were diagnosed with pleomorphic carcinoma as determined by the three pathologists in our institute.
RESULTS: The 21 study subjects consisted of 18 male and 3 female patients. The locations of the lesions were as follows: 13 cases, right upper lobe; 5 cases, left upper lobe; 2 cases, right lower lobe; and 1 case, left lower lobe. The mean diameter of the tumor in this series was 55.2 mm (17-100 mm). As for the pathological stage, four cases were stage IA, seven cases were stage IB, five cases were stage IIB, two cases were stage IIIA, and three cases were stage IIIB. The overall 5-year survival rate was 80.0%. There were no significant differences between the symptomatic group and the asymptomatic group, or between the p-factor positive group and the p-factor negative group. On the other hand, there was a significant difference in the disease-free survival rate between the node negative group and the node positive group, and there was also a significant difference in the overall survival rate between the curative operation group and the non-curative operation group.
CONCLUSIONS: In this clinical study, the presence of lymph node metastasis and the treatment by a curative resection of the tumor were the most important prognostic factors for pulmonary pleomorphic carcinoma. However, further investigation of a large number of cases is needed in order to gain a clearer understanding of the clinical characteristics and behavior of pleomorphic carcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17942316     DOI: 10.1016/j.ejcts.2007.09.010

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Clinicopathological factors influenced the prognosis of surgically resected pulmonary pleomorphic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Ryoichi Nakanishi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

3.  Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.

Authors:  Takahide Kodama; Kunihiko Miyazaki; Hiroaki Satoh; Shigemi Hitomi; Morio Ohtsuka
Journal:  Med Oncol       Date:  2008-10-21       Impact factor: 3.064

4.  Surgical treatment for pulmonary pleomorphic carcinoma: A retrospective study of 60 patients.

Authors:  Chunyu Ji; Chenxi Zhong; Wentao Fang; Heng Zhao
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

5.  Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung.

Authors:  Tomohiro Tamura; Gen Ohara; Katsunori Kagohashi; Mio Kawaguchi; Koichi Kurishima; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2016-01-29

6.  Perioperative change in neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor in patients with completely resected primary pulmonary sarcomatoid carcinoma.

Authors:  Yong Won Seong; Sung Joon Han; Woohyun Jung; Jae Hyun Jeon; Sukki Cho; Sanghoon Jheon; Kwhanmien Kim
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

7.  Clinicopathological characteristics and prognosis of pulmonary pleomorphic carcinoma: a population-based retrospective study using SEER data.

Authors:  Jiacheng Yin; Yong Yang; Ke Ma; Xiaodong Yang; Tao Lu; Shuai Wang; Yu Shi; Cheng Zhan; Yimeng Zhu; Qun Wang
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

8.  Coexistent lung adenocarcinoma and giant cell carcinoma in different lung lobes of the same patient.

Authors:  Yan Li; Shiping Song; Chang-Qing Bai; Xiao-Bing Li; Wen-Kai Niu; Xue-Yi Shang
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

9.  Laparoscopic adrenalectomy for solitary adrenal metastasis from lung cancer.

Authors:  Noriyasu Kawai; Keiichi Tozawa; Takahiro Yasui; Yoshinobu Moritoki; Hidefumi Sasaki; Motoki Yano; Yoshitaka Fujii; Kenjiro Kohri
Journal:  JSLS       Date:  2014 Jul-Sep       Impact factor: 2.172

Review 10.  Pulmonary pleomorphic carcinoma: A case report and review of the literature.

Authors:  Xiangwei Zhang; Yang Wang; Linping Zhao; Haiyan Jing; Shaowei Sang; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.